Resistance of digestive system malignancies to Claudin 18.2–targeting therapy: Mechanistic heterogeneity, tumor ecosystem remodeling, and rational precision strategies
Publication date: January 2027 Source: Drug Resistance Updates, Volume 90 Author(s): Qian Wang, Tao Yang, Ning Liang, Peng Gao, Shuai Zhou, Xiongchao Fang, Qing Qiao, Xianli He, Nan Wang, Gang Wang
Resistance of digestive system malignancies to Claudin 18.2–targeting therapy: Mechanistic heterogeneity, tumor ecosystem remodeling, and rational precision strategies. // Drug Resistance Updates. – URL: https://www.sciencedirect.com/science/article/pii/S136876462600155X?dgcid=rss_sd_all
Resistance of digestive system malignancies to Claudin 18.2–targeting therapy: Mechanistic heterogeneity, tumor ecosystem remodeling, and rational precision strategies. Drug Resistance Updates. https://www.sciencedirect.com/science/article/pii/S136876462600155X?dgcid=rss_sd_all
“Resistance of digestive system malignancies to Claudin 18.2–targeting therapy: Mechanistic heterogeneity, tumor ecosystem remodeling, and rational precision strategies.” Drug Resistance Updates.
@article{article43490,
title = {Resistance of digestive system malignancies to Claudin 18.2–targeting therapy: Mechanistic heterogeneity, tumor ecosystem remodeling, and rational precision strategies},
journal = {Drug Resistance Updates},
url = {https://www.sciencedirect.com/science/article/pii/S136876462600155X?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...